With BioHale®, our new excipient portfolio for biologics, we offer the highest purity excipients to be used in formulation. The first two excipients BioHale® Trehalose and BioHale® Sucrose are currently under development. Samples of these new products are now available.
DFE Pharma’s continuity of excipient production in the Netherlands (5), Germany (1), India (2) and New Zealand (2) has not been affected by COVID-19. Even so, the local governments (e.g. the Netherlands, Germany, India and New Zealand) have classified the pharmaceutical industry as critical within the measures taken to prevent further COVID-19 spread, meaning, DFE Pharma is asked to continue to produce your excipients on time in full within the agreed quality parameters. Learn more about how we have mitigated our risk for production and supply.
We develop, produce and supply excipients for use in oral solid dose and dry powder inhalation, but as a supplier of complete solutions we do a lot more than that. We work closely with pharmaceutical companies around the world, collaborating in original research, supporting their go to market strategies and fine-tuning our products to ensure that their medicines deliver exactly the right outcomes for patients.
That makes us more than just a supplier. We are recognised as a true partner to the pharmaceutical industry in helping people round the world lead healthier lives.
We have spent more than 100 years in proving that excellence is not just a word but a deep, long-term commitment to our customers and to the millions of patients who use our products every day. Our customers respect us for product quality, technical expertise and hands-on market support. We work with your future in mind: today, tomorrow and always.
Our portfolio consists of filler/binders (Lactose, Microcrystalline Cellulose, Starches), superdisintegrants (Croscarmellose Sodium and Sodium Starch Glycolate) for oral solid dose and carriers for inhalation (Lactose).
Office
Distributor
